Cubist Systematic Strategies’s Phathom Pharmaceuticals PHAT Stock Holding History

Cubist Systematic Strategies’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-282,553	Closed	-$2.29M	–	3366
2024 Q4	$2.29M	Buy	+282,553	New	+$3.5M	0.01%	1270
2023 Q2	–	Sell	-1,649	Closed	-$11.8K	–	4121
2023 Q1	$11.8K	Buy	+1,649	New	+$14.5K	﹤0.01%	3709
2022 Q4	–	Sell	-18,294	Closed	-$203K	–	4521
2022 Q3	$203K	Buy	+18,294	New	+$174K	﹤0.01%	3751

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Cubist Systematic Strategies's PHAT Position: Q1 2025 in Review

Cubist Systematic Strategies sold out of Phathom Pharmaceuticals (PHAT) in Q1 2025, closing a stake of 282,553 shares — an estimated $2.29M sold.

Cubist Systematic Strategies first reported a position in PHAT in Q3 2022 and held it in 3 quarters. The position peaked at $2.29M in Q4 2024. 137 funds tracked by Wall St. Rank hold PHAT as of Q1 2025.

Cubist Systematic Strategies reported no remaining Phathom Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Cubist Systematic Strategies sold 282,553 Phathom Pharmaceuticals shares in Q1 2025, an estimated $2.29M.
Cubist Systematic Strategies first reported a position in Phathom Pharmaceuticals in Q3 2022 and held it in 3 quarters.
Cubist Systematic Strategies's Phathom Pharmaceuticals position peaked at $2.29M in Q4 2024.
137 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2025.

Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.